Hong Ki Yong, Kim Il-Kug, Sakong Yong, Park Bo-Yoon, Jin Ung Sik
From the Department of Plastic and Reconstructive Surgery, Seoul National University Hospital, Seoul National University College of Medicine.
Department of Plastic and Reconstructive Surgery, Yeungnam University College of Medicine.
Plast Reconstr Surg. 2023 Apr 1;151(4):717-726. doi: 10.1097/PRS.0000000000009985. Epub 2022 Dec 5.
Although implant-based breast reconstruction is a common surgical modality, a periprosthetic capsule inevitably forms and worsens in cases of postmastectomy radiation therapy. Previous animal studies have reported that antiadhesive agents (AAAs) inhibit periprosthetic capsule formation. The authors prospectively examined the clinical effects of an AAA (Mediclore) on capsule formation in implant-based breast reconstruction.
The authors analyzed patients who underwent immediate two-stage implant-based breast reconstruction following total mastectomy for breast malignancy between November of 2018 and March of 2019. Each patient was randomly allocated to the control or AAA group. After inserting the breast expander and acellular dermal matrix, AAA was applied around the expander before skin closure. The capsule specimen was obtained during the expander-implant change; capsule thickness and immunohistochemistry were investigated.
A total of 48 patients were enrolled and allocated to the control ( n = 22) and AAA ( n = 26) groups. There were no significant differences in patient- and operation-related characteristics. Submuscular capsule thickness was significantly reduced in the AAA group compared with the control group. The levels of pro-capsular-forming cells (myofibroblasts, fibroblasts, and M1 macrophages) in the capsule were significantly lower in the AAA group than in the control group.
AAA reduced the thickness of periprosthetic capsules and changed the profiles of cells involved in capsule formation during the tissue expansion. These findings demonstrate the clinical value of AAA for mitigating capsule formation in implant-based breast reconstruction.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.
尽管植入式乳房重建是一种常见的手术方式,但在乳房切除术后放疗的情况下,假体周围的包膜不可避免地会形成并恶化。先前的动物研究报告称,抗粘连剂(AAA)可抑制假体周围包膜的形成。作者前瞻性地研究了一种抗粘连剂(Mediclore)在植入式乳房重建中对包膜形成的临床效果。
作者分析了2018年11月至2019年3月期间因乳腺恶性肿瘤接受全乳切除术后立即进行两阶段植入式乳房重建的患者。每位患者被随机分配到对照组或抗粘连剂组。在插入乳房扩张器和脱细胞真皮基质后,在关闭皮肤前将抗粘连剂应用于扩张器周围。在扩张器更换为永久假体时获取包膜标本;研究包膜厚度和免疫组织化学。
共纳入48例患者,分为对照组(n = 22)和抗粘连剂组(n = 26)。患者和手术相关特征无显著差异。与对照组相比,抗粘连剂组的肌下包膜厚度显著降低。抗粘连剂组包膜中促包膜形成细胞(肌成纤维细胞、成纤维细胞和M1巨噬细胞)的水平显著低于对照组。
抗粘连剂在组织扩张过程中降低了假体周围包膜的厚度,并改变了参与包膜形成的细胞特征。这些发现证明了抗粘连剂在减轻植入式乳房重建中包膜形成方面的临床价值。
临床问题/证据水平:治疗性,II级。